Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis.

In biological fluids, proteins associate with nanoparticles, leading to a protein "corona" defining the biological identity of the particle. However, a comprehensive knowledge of particle-guided protein fingerprints and their dependence on nanomaterial properties is incomplete. We studied the long-lived ("hard") blood plasma derived corona on monodispersed amorphous silica nanoparticles differing in size (20, 30, and 100 nm). Employing label-free liquid chromatography mass spectrometry, one- and two-dimensional gel electrophoresis, and immunoblotting the composition of the protein corona was analyzed not only qualitatively but also quantitatively. Detected proteins were bioinformatically classified according to their physicochemical and biological properties. Binding of the 125 identified proteins did not simply reflect their relative abundance in the plasma but revealed an enrichment of specific lipoproteins as well as proteins involved in coagulation and the complement pathway. In contrast, immunoglobulins and acute phase response proteins displayed a lower affinity for the particles. Protein decoration of the negatively charged particles did not correlate with protein size or charge, demonstrating that electrostatic effects alone are not the major driving force regulating the nanoparticle-protein interaction. Remarkably, even differences in particle size of only 10 nm significantly determined the nanoparticle corona, although no clear correlation with particle surface volume, protein size, or charge was evident. Particle size quantitatively influenced the particle's decoration with 37% of all identified proteins, including (patho)biologically relevant candidates. We demonstrate the complexity of the plasma corona and its still unresolved physicochemical regulation, which need to be considered in nanobioscience in the future.

[1]  Iseult Lynch,et al.  Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. , 2011, Journal of the American Chemical Society.

[2]  Sara Linse,et al.  Modeling the Time Evolution of the Nanoparticle-Protein Corona in a Body Fluid , 2010, PloS one.

[3]  M. Maskos,et al.  Characterization of polymer nanoparticles by asymmetrical flow field flow fractionation (AF-FFF). , 2010, Journal of nanoscience and nanotechnology.

[4]  Albert Duschl,et al.  Time evolution of the nanoparticle protein corona. , 2010, ACS nano.

[5]  Parag Aggarwal,et al.  Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. , 2008, Molecular pharmaceutics.

[6]  Benjamin Gilbert,et al.  Extracellular Proteins Limit the Dispersal of Biogenic Nanoparticles , 2007, Science.

[7]  Mauro Ferrari,et al.  Nanogeometry: beyond drug delivery. , 2008, Nature nanotechnology.

[8]  James S Murday,et al.  Translational nanomedicine: status assessment and opportunities. , 2009, Nanomedicine : nanotechnology, biology, and medicine.

[9]  Christoph Alexiou,et al.  Targeting cancer cells: magnetic nanoparticles as drug carriers , 2006, European Biophysics Journal.

[10]  M. Reilly,et al.  HDL proteomics: pot of gold or Pandora's box? , 2007, The Journal of clinical investigation.

[11]  M. Dobrovolskaia,et al.  Immunological properties of engineered nanomaterials , 2007, Nature Nanotechnology.

[12]  Francesco Stellacci,et al.  Effect of surface properties on nanoparticle-cell interactions. , 2010, Small.

[13]  Iseult Lynch,et al.  Protein-nanoparticle interactions: What does the cell see? , 2009, Nature nanotechnology.

[14]  Yuval Golan,et al.  The role of interparticle and external forces in nanoparticle assembly. , 2008, Nature materials.

[15]  Marina A Dobrovolskaia,et al.  Evaluation of nanoparticle immunotoxicity. , 2009, Nature nanotechnology.

[16]  B. Adryan,et al.  Analysis of differentially expressed proteins in oral squamous cell carcinoma by MALDI-TOF MS. , 2011, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[17]  W. Witke,et al.  Gelsolin and diseases. , 2007, Sub-cellular biochemistry.

[18]  U. Goldbourt,et al.  Apolipoproteins and long-term prognosis in coronary heart disease patients. , 2009, American heart journal.

[19]  Jerzy Leszczynski,et al.  Bionanoscience: Nano meets bio at the interface. , 2010, Nature nanotechnology.

[20]  W. Mann,et al.  An otoprotective role for the apoptosis inhibitor protein survivin , 2010, Cell Death and Disease.

[21]  Toshiro Hirai,et al.  Amorphous nanosilica induce endocytosis-dependent ROS generation and DNA damage in human keratinocytes , 2011, Particle and Fibre Toxicology.

[22]  N Leigh Anderson,et al.  High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. , 2008, Clinical chemistry.

[23]  Sara Linse,et al.  Complete high‐density lipoproteins in nanoparticle corona , 2009, The FEBS journal.

[24]  R. Aebersold,et al.  A High-Confidence Human Plasma Proteome Reference Set with Estimated Concentrations in PeptideAtlas* , 2011, Molecular & Cellular Proteomics.

[25]  P. Janmey,et al.  Plasma gelsolin: function, prognostic value, and potential therapeutic use. , 2008, Current protein & peptide science.

[26]  Scott E McNeil,et al.  Nanoparticle therapeutics: a personal perspective. , 2009, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[27]  T. Xia,et al.  Understanding biophysicochemical interactions at the nano-bio interface. , 2009, Nature materials.

[28]  Reinhard Zellner,et al.  The influence of surface composition of nanoparticles on their interactions with serum albumin. , 2010, Chemphyschem : a European journal of chemical physics and physical chemistry.

[29]  J. Klein Probing the interactions of proteins and nanoparticles , 2007, Proceedings of the National Academy of Sciences.

[30]  Scott E McNeil,et al.  Nanomaterial standards for efficacy and toxicity assessment. , 2010, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[31]  Parag Aggarwal,et al.  Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. , 2009, Advanced drug delivery reviews.

[32]  Wolfgang J Parak,et al.  A quantitative fluorescence study of protein monolayer formation on colloidal nanoparticles. , 2009, Nature nanotechnology.

[33]  Susan M Resnick,et al.  Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. , 2010, Archives of general psychiatry.

[34]  S. Hanash,et al.  BiomarkerDigger: A versatile disease proteome database and analysis platform for the identification of plasma cancer biomarkers , 2009, Proteomics.

[35]  Kenneth A. Dawson,et al.  Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts , 2008, Proceedings of the National Academy of Sciences.

[36]  Parag Aggarwal,et al.  Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. , 2009, Nanomedicine : nanotechnology, biology, and medicine.

[37]  Christine Pohl,et al.  Inflammatory and cytotoxic responses of an alveolar-capillary coculture model to silica nanoparticles: Comparison with conventional monocultures , 2011, Particle and Fibre Toxicology.

[38]  R. Müller,et al.  Influence of surface charge density on protein adsorption on polymeric nanoparticles: analysis by two-dimensional electrophoresis. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[39]  D. Begley,et al.  Human serum albumin nanoparticles modified with apolipoprotein A-I cross the blood-brain barrier and enter the rodent brain , 2010, Journal of drug targeting.

[40]  Darren J. Martin,et al.  Differential plasma protein binding to metal oxide nanoparticles , 2009, Nanotechnology.

[41]  M. Gorenstein,et al.  Absolute Quantification of Proteins by LCMSE , 2006, Molecular & Cellular Proteomics.

[42]  Rainer H Müller,et al.  Functional groups on polystyrene model nanoparticles: influence on protein adsorption. , 2003, Journal of biomedical materials research. Part A.

[43]  Iseult Lynch,et al.  What the cell "sees" in bionanoscience. , 2010, Journal of the American Chemical Society.

[44]  T. Xia,et al.  Potential health impact of nanoparticles. , 2009, Annual review of public health.

[45]  Stefan Tenzer,et al.  Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. , 2009, Nature immunology.

[46]  Sara Linse,et al.  Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles , 2007, Proceedings of the National Academy of Sciences.

[47]  M. Mahmoudi,et al.  Protein-nanoparticle interactions: opportunities and challenges. , 2011, Chemical reviews.

[48]  R. Marschalek,et al.  Cell-based Analysis of Structure-Function Activity of Threonine Aspartase 1* , 2010, The Journal of Biological Chemistry.

[49]  Subramaniam Pennathur,et al.  Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. , 2007, The Journal of clinical investigation.

[50]  Anil K Patri,et al.  Method for analysis of nanoparticle hemolytic properties in vitro. , 2008, Nano letters.

[51]  Jack F Douglas,et al.  Interaction of gold nanoparticles with common human blood proteins. , 2010, ACS nano.

[52]  Gilbert S Omenn,et al.  Data management and data integration in the HUPO plasma proteome project. , 2011, Methods in molecular biology.

[53]  M. Morandi,et al.  Nanoparticle‐induced platelet aggregation and vascular thrombosis , 2005, British journal of pharmacology.

[54]  Mauro Ferrari,et al.  Nanomedicine--challenge and perspectives. , 2009, Angewandte Chemie.

[55]  Sara Linse,et al.  Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. , 2007, Angewandte Chemie.

[56]  Mark J DiNubile Plasma gelsolin as a biomarker of inflammation , 2008, Arthritis research & therapy.

[57]  Sara Linse,et al.  The nanoparticle-protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century. , 2007, Advances in colloid and interface science.

[58]  Feng Zhang,et al.  Quantitative analysis of the protein corona on FePt nanoparticles formed by transferrin binding , 2010, Journal of The Royal Society Interface.